ATI RN
Cardiovascular System Exam
1. What condition involves the heart's electrical system malfunctioning, causing very fast heartbeats originating from the ventricles?
- A. Ventricular tachycardia
- B. Atrial fibrillation
- C. Supraventricular tachycardia
- D. Bradycardia
Correct answer: A
Rationale: Ventricular tachycardia is the correct answer. It is a condition characterized by the heart's electrical system malfunctioning, leading to very fast heartbeats originating from the ventricles. Ventricular tachycardia can be life-threatening as it may progress to ventricular fibrillation, causing cardiac arrest. Atrial fibrillation (choice B) involves rapid, irregular beating of the atria, not the ventricles. Supraventricular tachycardia (choice C) originates above the ventricles and does not involve ventricular malfunction. Bradycardia (choice D) is the opposite of tachycardia, characterized by an abnormally slow heart rate.
2. A client on spironolactone (Aldactone) has a potassium level of 6.0 mEq/L. What is the nurse’s priority action?
- A. Hold the spironolactone and notify the healthcare provider.
- B. Administer a potassium supplement.
- C. Continue the spironolactone as ordered.
- D. Increase the dose of spironolactone.
Correct answer: A
Rationale: The correct action for a client on spironolactone with a potassium level of 6.0 mEq/L is to hold the medication and notify the healthcare provider. Spironolactone is a potassium-sparing diuretic that can further elevate potassium levels, which are already high. Administering a potassium supplement (Choice B) would exacerbate the hyperkalemia. Continuing the spironolactone as ordered (Choice C) could lead to worsening hyperkalemia. Increasing the dose of spironolactone (Choice D) would be contraindicated in the presence of elevated potassium levels.
3. What is a condition where the lung's air sacs (alveoli) are damaged and enlarged, leading to breathlessness?
- A. Emphysema
- B. Chronic bronchitis
- C. Asthma
- D. Pulmonary fibrosis
Correct answer: A
Rationale: Emphysema is the correct answer. It is a condition where the air sacs in the lungs are damaged and enlarged, leading to breathlessness. Chronic bronchitis is characterized by inflammation of the bronchial tubes, not the alveoli. Asthma involves airway inflammation and constriction, not alveolar damage. Pulmonary fibrosis is a condition where lung tissue becomes thickened and scarred, different from the alveolar damage seen in emphysema.
4. Which medication is used to prevent blood clots by thinning the blood, reducing the risk of stroke and heart attack?
- A. Anticoagulant
- B. ACE inhibitor
- C. Beta-blocker
- D. Calcium channel blocker
Correct answer: A
Rationale: The correct answer is 'Anticoagulant.' Anticoagulants are medications specifically designed to prevent blood clots by thinning the blood, which effectively reduces the risk of stroke, heart attack, and other cardiovascular events. Choices B, C, and D, which are ACE inhibitors, beta-blockers, and calcium channel blockers, respectively, do not have the primary mechanism of action to prevent blood clot formation. ACE inhibitors, beta-blockers, and calcium channel blockers are commonly used for managing hypertension and other cardiovascular conditions by different mechanisms of action.
5. Which condition is characterized by the lungs becoming scarred and stiff, leading to difficulty breathing and inadequate oxygen intake into the bloodstream?
- A. Pulmonary fibrosis
- B. Cystic fibrosis
- C. COPD
- D. Tuberculosis
Correct answer: A
Rationale: The correct answer is A, Pulmonary fibrosis. Pulmonary fibrosis is a lung disease where lung tissue is damaged and scarred, resulting in breathing difficulties and decreased oxygen transfer into the bloodstream. Cystic fibrosis (B) is a genetic disorder primarily affecting the lungs and digestive system, not causing lung scarring. COPD (C) includes conditions like chronic bronchitis and emphysema but doesn't specifically involve lung scarring. Tuberculosis (D) is a bacterial infection that primarily affects the lungs but doesn't cause lung tissue scarring and stiffness as seen in pulmonary fibrosis.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access